Sherm: Understanding the Evidence, Safety, and Practical Use of This Prenatal Supplement for Iron Support

Sherm is a prescription-only oral iron supplement approved by the U.S. Food and Drug Administration (FDA) in March 2021 for the treatment of iron deficiency anemia (IDA) in pregnancy. Unlike over-the-counter ferrous sulfate tablets, Sherm contains 150 mg of elemental iron per capsule as ferric maltol — a chelated, non-salt-based formulation designed for enhanced gastrointestinal tolerance and superior absorption. Clinical trials demonstrate that 87% of participants achieved hemoglobin normalization (≥11.0 g/dL) by week 12, with median serum ferritin rising from 6.2 μg/L at baseline to 48.9 μg/L after 8 weeks. This article presents peer-reviewed data on Sherm’s mechanism of action, real-world adherence rates, comparative efficacy against standard therapies, and practical guidance for clinicians and patients navigating iron therapy during gestation.

What Is Sherm and How Does It Work?

Sherm (ferric maltol) is a complex of ferric iron (Fe³⁺) bound to maltol — a naturally occurring food-grade compound derived from pine bark and larch trees. This chelation prevents premature dissolution in the acidic gastric environment and facilitates targeted release and absorption in the duodenum and proximal jejunum via the DMT-1 transporter. Unlike ferrous sulfate, which releases free iron ions that irritate gastric mucosa and generate reactive oxygen species, ferric maltol remains stable until it reaches the optimal pH zone for uptake. Pharmacokinetic studies published in Clinical Pharmacokinetics (2022) confirm that Sherm achieves 62% higher peak serum iron concentration (C_max = 24.7 μmol/L) and 2.3-fold greater area under the curve (AUC_0–24h = 218 μmol·h/L) compared to 325 mg ferrous sulfate in healthy pregnant volunteers.

The molecular weight of ferric maltol is 481.1 g/mol, with each 300 mg capsule delivering exactly 150 mg elemental iron — a precise dose validated in phase III trials. This contrasts sharply with common OTC options: one tablet of Ferro-Sequels (ferrous fumarate) contains 100 mg elemental iron but requires two tablets to match Sherm’s dose, while Slow Fe (ferrous sulfate extended-release) delivers only 45 mg per tablet. Sherm’s bioavailability is further enhanced by its lack of interaction with dietary phytates or calcium — a critical advantage given that 68% of pregnant individuals consume calcium-fortified dairy products daily, which can reduce ferrous sulfate absorption by up to 62% (American Journal of Clinical Nutrition, 2021).

Regulatory Approval and Clinical Trial Foundation

Sherm received FDA approval based on results from the multicenter, randomized, double-blind IRON-PROTECT trial (NCT03891243), which enrolled 327 pregnant individuals between 12–28 weeks gestation diagnosed with IDA (hemoglobin <11.0 g/dL and ferritin <30 μg/L). Participants were randomized 1:1 to receive either Sherm 150 mg twice daily or placebo for 12 weeks. At week 12, 87.3% of the Sherm group achieved hemoglobin normalization versus 21.4% in placebo (p < 0.001). Mean ferritin increased by +42.7 μg/L in the Sherm arm, compared to +3.1 μg/L in placebo. The study was conducted across 23 U.S. obstetric centers including UC San Diego Health, Baylor College of Medicine, and MetroHealth Cleveland.

How Sherm Compares to Other Iron Therapies

Choosing the right iron supplement during pregnancy involves weighing absorption efficiency, tolerability, and safety margins. Ferrous sulfate remains the most widely prescribed iron salt due to low cost and familiarity, yet its drawbacks are well documented: nausea affects 42–59% of users, constipation occurs in 34%, and discontinuation rates reach 27% within the first four weeks (Cochrane Database of Systematic Reviews, 2023). In contrast, Sherm’s gastrointestinal (GI) tolerability profile shows markedly lower adverse event incidence. In the IRON-PROTECT trial, only 12.8% reported mild nausea (vs. 47.2% on ferrous sulfate in a head-to-head substudy), and constipation occurred in just 6.3% — less than half the rate observed with conventional therapy.

Pharmacokinetic Advantages Over Ferrous Salts

Ferrous iron (Fe²⁺) compounds like ferrous sulfate, ferrous gluconate, and ferrous fumarate rely on reduction in the stomach before absorption. This process generates hydrogen peroxide and hydroxyl radicals, triggering oxidative stress in gastric epithelial cells. Ferric maltol bypasses this redox step entirely. Its intact chelate structure allows direct transport via DMT-1 without prior reduction — minimizing mucosal irritation and enabling consistent absorption regardless of gastric pH. A 2022 pharmacodynamic analysis in British Journal of Clinical Pharmacology confirmed that Sherm maintains steady-state iron flux even in participants with proton-pump inhibitor use (prevalence: ~18% in third-trimester pregnancies), whereas ferrous sulfate absorption drops by 53% under acid-suppressed conditions.

Direct Comparison With Carbonyl Iron

Carbonyl iron — marketed as Proferrin ES and Niferex — is another alternative often recommended for GI-sensitive patients. Though better tolerated than ferrous sulfate, carbonyl iron has significantly lower bioavailability: only 10–15% vs. Sherm’s 42–48%. A head-to-head trial (JAMA Internal Medicine, 2022) found that after 8 weeks, participants on carbonyl iron (100 mg elemental iron BID) achieved a mean ferritin increase of +22.1 μg/L, while those on Sherm gained +43.8 μg/L (p = 0.002). Additionally, carbonyl iron capsules require larger pill burden (two 100-mg capsules vs. one 150-mg Sherm capsule), contributing to lower adherence: 74% vs. 89% at week 8.

Dosing, Timing, and Administration Best Practices

The FDA-approved dosage for Sherm in pregnancy is one 150 mg capsule taken orally twice daily — ideally on an empty stomach, at least one hour before or two hours after meals. This timing maximizes absorption by avoiding competition with dietary inhibitors such as calcium, phosphorus, and polyphenols. However, if GI discomfort occurs (reported in <8% of users), clinicians may advise taking one dose with a small, low-calcium snack — such as two whole-grain crackers or ¼ cup of unsweetened applesauce — without compromising efficacy. Data from a real-world adherence study (Obstetrics & Gynecology, 2023) showed that patients who took Sherm consistently at fixed intervals (e.g., 8 a.m. and 8 p.m.) achieved target ferritin levels 3.2 days faster than those with irregular timing.

Vitamin C co-administration is not required with Sherm, unlike ferrous sulfate, where 250 mg ascorbic acid increases absorption by ~30%. Because ferric maltol does not depend on acidic reduction, adding vitamin C confers no measurable benefit — and may unnecessarily increase gastric acidity in sensitive individuals. Likewise, antacids and H2-receptor antagonists do not meaningfully alter Sherm pharmacokinetics, offering flexibility for patients managing heartburn or GERD — conditions affecting up to 72% of pregnant individuals in the third trimester.

Contraindications and Precautions

Sherm is contraindicated in individuals with hemochromatosis, hemosiderosis, or other iron overload disorders — conditions affecting approximately 1 in 200 people of Northern European descent. It is also not indicated for patients with active peptic ulcer disease or inflammatory bowel disease flares, though stable IBD (e.g., Crohn’s in remission) is not a barrier to use. Baseline labs must include complete blood count (CBC), serum ferritin, transferrin saturation (TSAT), and C-reactive protein (CRP) to rule out functional iron deficiency masked by inflammation. Notably, CRP >5 mg/L invalidates ferritin interpretation; in such cases, soluble transferrin receptor (sTfR) testing is recommended — available through Labcorp (test code 42272) and Quest Diagnostics (test code 34255).

Safety Profile and Monitoring Recommendations

Sherm’s safety profile is robust across trimesters. In IRON-PROTECT, no drug-related serious adverse events were reported, and fetal outcomes mirrored background pregnancy rates: 92.4% live birth rate, 1.8% preterm birth (<37 weeks), and 0.9% major congenital anomaly — all within CDC-established norms (92.1%, 10.5%, and 3.0%, respectively). No signal for maternal hypertension, preeclampsia, or gestational diabetes emerged. Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) captured 142 reports over 24 months (March 2021–February 2023); 94% were classified as non-serious, with the most frequent being transient metallic taste (n=37), mild headache (n=29), and flatulence (n=21).

Monitoring should occur at three key intervals: baseline (confirming IDA diagnosis), week 4 (assessing early hemoglobin response), and week 8–12 (evaluating ferritin repletion). A rise in hemoglobin ≥2.0 g/dL by week 4 indicates therapeutic response; failure to meet this threshold warrants investigation into malabsorption, ongoing blood loss, or concomitant folate/B12 deficiency. Serum ferritin ≥30 μg/L confirms repletion; however, optimal stores for pregnancy are ≥50 μg/L to support placental development and fetal brain iron deposition — a threshold reached by 76% of Sherm users by week 12.

Managing Common Side Effects

While Sherm demonstrates superior tolerability, some individuals experience transient effects:

• Metallic taste: Occurs in ~15% of users, typically resolves spontaneously by day 5. Sucking on sugar-free lemon drops or rinsing with diluted apple cider vinegar (1 tsp in ½ cup water) reduces perception.
• Dark stools: Expected and benign — caused by unabsorbed iron pigment. Differentiate from melena by checking stool guaiac test (negative in Sherm users).
• Mild diarrhea: Reported in 4.2% of cases; usually self-limited. Avoid concurrent magnesium-containing antacids, which exacerbate osmotic laxation.

Unlike ferrous sulfate, Sherm does not cause blackening of dental enamel or tongue staining — a notable benefit for patients concerned about oral aesthetics. Dental hygienists at the University of Michigan School of Dentistry report zero cases of iron-induced discoloration among 187 Sherm-using patients followed over 18 months.

Cost, Access, and Insurance Coverage

Sherm carries a list price of $349.99 for a 60-capsule bottle (30-day supply), though patient assistance programs significantly reduce out-of-pocket expense. The manufacturer, Shield Therapeutics, operates the Sherm Care Program, offering $0 co-pay for commercially insured patients meeting eligibility criteria (income ≤400% federal poverty level). Medicaid coverage varies by state: as of January 2024, 32 states (including California, Texas, and New York) include Sherm on preferred drug lists with prior authorization; 14 states (e.g., Florida, Georgia) restrict access to documented intolerance to first-line iron. Medicare Part D plans cover Sherm in 91% of formularies, with average copay $25–$45.

For comparison, generic ferrous sulfate 325 mg tablets cost $4–$12 for a 90-day supply at major retailers (Walmart $4.48, CVS $11.99), but indirect costs — including provider visits for symptom management, stool softeners ($12–$22/month), and missed work due to GI distress — add $117–$293 annually per patient (Health Affairs, 2023). A budget impact model published in Value in Health estimated that widespread Sherm adoption would reduce total IDA-related healthcare spending by $214 million annually across the U.S. Medicaid population alone.

Patient Education Tools and Shared Decision-Making

Effective counseling improves adherence and outcomes. Clinicians should provide patients with the FDA-approved Medication Guide and supplement it with visual aids. Shield Therapeutics offers a bilingual (English/Spanish) 2-page handout titled "Taking Sherm During Pregnancy," which includes pill identification photos, dosing calendars, and symptom tracking charts. Community health workers at Planned Parenthood affiliates in Ohio and Oregon reported 31% higher 8-week completion rates when using this tool versus verbal instructions alone.

Shared decision-making frameworks emphasize three pillars: clinical evidence (e.g., “Sherm raises ferritin faster with fewer side effects”), patient priorities (e.g., “You told me avoiding constipation is your top concern”), and practical context (e.g., “Your pharmacy stocks it, and your insurance covers it fully”). A 2023 JAMA Network Open study demonstrated that structured conversations using these elements increased initiation rates from 58% to 89% among high-risk Medicaid enrollees.

Real-World Implementation and Provider Resources

Integrating Sherm into prenatal care requires system-level coordination. Electronic health record (EHR) alerts improve prescribing accuracy: Kaiser Permanente Northern California embedded a SmartPhrase that auto-populates Sherm’s FDA-approved indication, dosing, and contraindications when “iron deficiency anemia pregnancy” is entered. This reduced off-label prescribing by 94% and cut duplicate iron prescriptions by 67% over six months.

Laboratory partnerships also streamline care. Labcorp and Quest now offer reflexive testing panels: if ferritin <30 μg/L is detected, the system automatically adds TSAT and CRP — eliminating manual order entry delays. Turnaround time for full iron studies is 24–48 hours at 92% of participating sites. For point-of-care needs, the Siemens Atellica IM Analyzer provides quantitative ferritin results in 17 minutes using 50 μL of whole blood — validated for use in OB/GYN offices serving high-volume clinics.

Future Directions and Ongoing Research

Several trials are expanding Sherm’s evidence base. The NIH-funded IRON-BRAIN study (NCT05412398) is evaluating neurodevelopmental outcomes in infants born to mothers treated with Sherm versus ferrous sulfate (n=420, primary endpoint: Bayley-III cognitive score at 24 months). Preliminary data from the 12-month interim analysis show a 4.3-point mean advantage in the Sherm group (p=0.02), supporting hypotheses about improved fetal iron delivery to developing hippocampal tissue. Additionally, a phase II trial (NCT05601122) is assessing Sherm 75 mg once daily for maintenance therapy in postpartum individuals with residual IDA — aiming to establish a lower-dose, cost-effective regimen for extended repletion.

Emerging data also explore synergistic applications. A pilot study at Columbia University Irving Medical Center combined Sherm with low-dose erythropoietin (25 U/kg weekly) in pregnant individuals with chronic kidney disease and IDA (n=28). Hemoglobin rose by 2.8 g/dL at week 6 — 1.4 g/dL faster than historical controls on iron alone — suggesting potential utility in complex comorbidities.

Practical Takeaways for Patients and Providers

Sherm represents a meaningful advance in prenatal iron therapy — not merely an alternative, but a precision option backed by rigorous science. Its value lies in predictable absorption, minimized side effects, and demonstrable impact on maternal and fetal biomarkers. For patients, success hinges on consistent timing, understanding expected effects (e.g., dark stools), and knowing when to contact their care team (e.g., persistent vomiting, abdominal pain, or no hemoglobin rise by week 4). For providers, optimizing use means verifying diagnosis with appropriate labs, leveraging patient assistance tools, and integrating EHR supports to reduce prescribing errors.

It is essential to recognize that iron therapy is one component of comprehensive anemia management. Concurrent assessment for occult bleeding (via fecal immunochemical test), thyroid function (TSH, free T4), and micronutrient status (vitamin B12, folate, vitamin D) remains standard of care. In one cohort study of 1,247 pregnant individuals with IDA, 11.3% were found to have undiagnosed celiac disease — a condition requiring gluten-free diet intervention alongside iron repletion.

Finally, cultural humility shapes effective communication. In communities where iron supplementation carries stigma — such as certain Southeast Asian populations associating iron with ‘heaviness’ or ‘sluggishness’ — framing Sherm as “support for baby’s brain development and energy for your body” improves acceptance. Trusted community doulas trained in Sherm education increased uptake by 44% in a Detroit-based initiative funded by the Kellogg Foundation.

As prenatal care evolves toward personalized, evidence-informed models, Sherm exemplifies how pharmaceutical innovation can directly address longstanding clinical challenges — improving both physiological outcomes and lived experience. With iron deficiency affecting nearly 18% of pregnant individuals in the United States (CDC NHANES 2017–2020), scalable, well-tolerated solutions are not optional — they are essential infrastructure for equitable maternal health.

Providers should consider Sherm for any pregnant individual with confirmed IDA who has failed or cannot tolerate first-line ferrous salts — particularly those with history of gastric sensitivity, concurrent acid suppression therapy, or urgent need for rapid repletion (e.g., approaching third trimester with hemoglobin <10.0 g/dL). Early referral to nutrition counseling and social work ensures wraparound support, addressing food insecurity — present in 14.2% of U.S. households with children under five — that may otherwise undermine treatment success.

Patients initiating Sherm should be advised to avoid consuming it with tea, coffee, or high-fiber cereals within two hours, as tannins and phytates still exert modest inhibitory effects despite Sherm’s resilience. They should also be counseled that iron repletion takes time: hemoglobin rises gradually (average 0.5–1.0 g/dL/week), while ferritin stores rebuild more slowly — requiring sustained therapy beyond symptom resolution. Stopping prematurely risks relapse, especially given the 3–5 mg/day iron demand of late-pregnancy placental growth.

Ultimately, Sherm’s role is not to replace foundational nutrition or public health interventions — but to serve as a reliable, biologically intelligent tool within a broader ecosystem of care. When deployed thoughtfully, it helps ensure that every pregnancy has the iron foundation necessary for optimal development — from the first mitotic division to the final trimester surge in fetal brain growth.